Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)

Bibliographic Details
Main Author: Kislaya, Irina
Publication Date: 2021
Other Authors: Gonçalves, Paulo, Barreto, Marta, De Sousa, Rita, Garcia, Ana Cristina, Matos, Rita, Guiomar, Raquel, Rodrigues, Ana Paula, ISNCOVID-19 group
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10400.18/7679
Summary: Introduction: The aim of this study was to estimate and describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies (immunoglobulin M and/or immunoglobulin G) in Portugal in May-July 2020. Material and methods: A cross-sectional seroepidemiological survey was developed after the peak of the first epidemic wave on a sample of 2301 Portuguese residents, aged 1 year or older. Survey sample was selected using a two-stage stratified non-probability sampling design (quota sampling). SARS-CoV-2 immunoglobulin M and immunoglobulin G antibodies were measured in serum samples by enzyme-linked immunosorbent assay. Seroprevalence estimates of immunoglobulin M and/or immunoglobulin G and 95% confidence intervals were stratified by sex, age group, health region and education. Results: Overall, seroprevalence was 2.9% (95% confidence interval: 2.0% - 4.2%). Higher prevalence rates were observed in male (4.1%, 95% confidence interval: 2.6% - 6.6%) and those with secondary education (6.4%, 95% confidence interval: 3.2% - 12.5%). Differences in seroprevalence by age group and region were not statistically significant. Discussion: The estimated seroprevalence of SARS-CoV-2 was higher than the cumulative incidence reported by the National Surveillance System but far from necessary to reach herd immunity. Conclusion: Our results support limited extent of infection by SARS-CoV-2 in the study population possibly due to early lockdown measures implemented in Portugal and support the need to continue monitoring of SARS-CoV-2 seroprevalence in order to increase our knowledge about the evolution of the epidemic and to estimate the proportion of the susceptible population over time.
id RCAP_c75658dbda684c523adb73be515ea4ba
oai_identifier_str oai:repositorio.insa.pt:10400.18/7679
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)Seroprevalência da Infecção por SARS-CoV-2 em Portugal em maio-julho de 2020: resultados do Primeiro Inquérito Serológico Nacional (ISNCOVID-19)COVID-19Immunoglobulin GImmunoglobulin MSARS-CoV-2SeroprevelenceSurveyCOVID-19 TestingAntibodies, ViralSeroepidemiologic StudiesAnticorpos AntiviraisEstudos SeroepidemiológicosImunoglobulina GImunoglobulina MTestagem COVID-19Estados de Saúde e de DoençaPortugalIntroduction: The aim of this study was to estimate and describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies (immunoglobulin M and/or immunoglobulin G) in Portugal in May-July 2020. Material and methods: A cross-sectional seroepidemiological survey was developed after the peak of the first epidemic wave on a sample of 2301 Portuguese residents, aged 1 year or older. Survey sample was selected using a two-stage stratified non-probability sampling design (quota sampling). SARS-CoV-2 immunoglobulin M and immunoglobulin G antibodies were measured in serum samples by enzyme-linked immunosorbent assay. Seroprevalence estimates of immunoglobulin M and/or immunoglobulin G and 95% confidence intervals were stratified by sex, age group, health region and education. Results: Overall, seroprevalence was 2.9% (95% confidence interval: 2.0% - 4.2%). Higher prevalence rates were observed in male (4.1%, 95% confidence interval: 2.6% - 6.6%) and those with secondary education (6.4%, 95% confidence interval: 3.2% - 12.5%). Differences in seroprevalence by age group and region were not statistically significant. Discussion: The estimated seroprevalence of SARS-CoV-2 was higher than the cumulative incidence reported by the National Surveillance System but far from necessary to reach herd immunity. Conclusion: Our results support limited extent of infection by SARS-CoV-2 in the study population possibly due to early lockdown measures implemented in Portugal and support the need to continue monitoring of SARS-CoV-2 seroprevalence in order to increase our knowledge about the evolution of the epidemic and to estimate the proportion of the susceptible population over time.Ordem dos MédicosRepositório Científico do Instituto Nacional de SaúdeKislaya, IrinaGonçalves, PauloBarreto, MartaDe Sousa, RitaGarcia, Ana CristinaMatos, RitaGuiomar, RaquelRodrigues, Ana PaulaISNCOVID-19 group2021-04-09T15:38:45Z2021-02-012021-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.18/7679eng1646-075810.20344/amp.15122info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-02-26T14:24:34Zoai:repositorio.insa.pt:10400.18/7679Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T21:39:44.557758Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
Seroprevalência da Infecção por SARS-CoV-2 em Portugal em maio-julho de 2020: resultados do Primeiro Inquérito Serológico Nacional (ISNCOVID-19)
title Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
spellingShingle Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
Kislaya, Irina
COVID-19
Immunoglobulin G
Immunoglobulin M
SARS-CoV-2
Seroprevelence
Survey
COVID-19 Testing
Antibodies, Viral
Seroepidemiologic Studies
Anticorpos Antivirais
Estudos Seroepidemiológicos
Imunoglobulina G
Imunoglobulina M
Testagem COVID-19
Estados de Saúde e de Doença
Portugal
title_short Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
title_full Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
title_fullStr Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
title_full_unstemmed Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
title_sort Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
author Kislaya, Irina
author_facet Kislaya, Irina
Gonçalves, Paulo
Barreto, Marta
De Sousa, Rita
Garcia, Ana Cristina
Matos, Rita
Guiomar, Raquel
Rodrigues, Ana Paula
ISNCOVID-19 group
author_role author
author2 Gonçalves, Paulo
Barreto, Marta
De Sousa, Rita
Garcia, Ana Cristina
Matos, Rita
Guiomar, Raquel
Rodrigues, Ana Paula
ISNCOVID-19 group
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório Científico do Instituto Nacional de Saúde
dc.contributor.author.fl_str_mv Kislaya, Irina
Gonçalves, Paulo
Barreto, Marta
De Sousa, Rita
Garcia, Ana Cristina
Matos, Rita
Guiomar, Raquel
Rodrigues, Ana Paula
ISNCOVID-19 group
dc.subject.por.fl_str_mv COVID-19
Immunoglobulin G
Immunoglobulin M
SARS-CoV-2
Seroprevelence
Survey
COVID-19 Testing
Antibodies, Viral
Seroepidemiologic Studies
Anticorpos Antivirais
Estudos Seroepidemiológicos
Imunoglobulina G
Imunoglobulina M
Testagem COVID-19
Estados de Saúde e de Doença
Portugal
topic COVID-19
Immunoglobulin G
Immunoglobulin M
SARS-CoV-2
Seroprevelence
Survey
COVID-19 Testing
Antibodies, Viral
Seroepidemiologic Studies
Anticorpos Antivirais
Estudos Seroepidemiológicos
Imunoglobulina G
Imunoglobulina M
Testagem COVID-19
Estados de Saúde e de Doença
Portugal
description Introduction: The aim of this study was to estimate and describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies (immunoglobulin M and/or immunoglobulin G) in Portugal in May-July 2020. Material and methods: A cross-sectional seroepidemiological survey was developed after the peak of the first epidemic wave on a sample of 2301 Portuguese residents, aged 1 year or older. Survey sample was selected using a two-stage stratified non-probability sampling design (quota sampling). SARS-CoV-2 immunoglobulin M and immunoglobulin G antibodies were measured in serum samples by enzyme-linked immunosorbent assay. Seroprevalence estimates of immunoglobulin M and/or immunoglobulin G and 95% confidence intervals were stratified by sex, age group, health region and education. Results: Overall, seroprevalence was 2.9% (95% confidence interval: 2.0% - 4.2%). Higher prevalence rates were observed in male (4.1%, 95% confidence interval: 2.6% - 6.6%) and those with secondary education (6.4%, 95% confidence interval: 3.2% - 12.5%). Differences in seroprevalence by age group and region were not statistically significant. Discussion: The estimated seroprevalence of SARS-CoV-2 was higher than the cumulative incidence reported by the National Surveillance System but far from necessary to reach herd immunity. Conclusion: Our results support limited extent of infection by SARS-CoV-2 in the study population possibly due to early lockdown measures implemented in Portugal and support the need to continue monitoring of SARS-CoV-2 seroprevalence in order to increase our knowledge about the evolution of the epidemic and to estimate the proportion of the susceptible population over time.
publishDate 2021
dc.date.none.fl_str_mv 2021-04-09T15:38:45Z
2021-02-01
2021-02-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.18/7679
url http://hdl.handle.net/10400.18/7679
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1646-0758
10.20344/amp.15122
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833599368391819264